A few days ago, Benzinga had the chance to chat with Cronos Group Inc (CVE: MJN) (OTC: PRMCF)’s president and CEO Michael Gorenstein and its head of marketing and
communications Eric Klein. The execs went into their business, the challenges
of exporting cannabis, recent corporate news and more.
Time To Meet Cronos
The Cronos Group is a fully and vertically integrated Canadian cannabis producer and distributor. It is also one of the largest
ones, outranked only by a handful of companies like CANOPY GROWTH CORP COM NPV (OTC: TWMJF), APHRIA INC COM NPV (OTC: APHQF) and AURORA CANNABIS IN COM NPV (OTC: ACBFF).
According to Gorenstein, this is the only Canadian producer with facilities and operations in multiple provinces. Their product
lines include:
- Peace Naturals, a medicinally focused LP in Ontario. “It is actually the first non-incumbent license to be
granted under the federally legal program,” Gorenstein said.
- In The Zone Produce, a British Columbia LP focused on the recreational market.
Other ventures include:
- A partnership with Pedanios to export cannabis to Germany.
- Indigenous Roots, a joint venture to create a brand with Canadian First Nations. “The group is led by Phil
Fontaine, the former National Chief of Assembly of First Nations,” Klein added. “We’re really focused on producing products for
indigenous people and communities that have been historically underserved from a medicinal standpoint,” he said. “We’re really
focused on taking social entrepreneurship to the next level. It’s about job creation and infrastructure building, and also wealth
creation for a group that’s traditionally been underserved,” Gorenstein went on.
- A 21 percent stake in Whistler Medical, “the only currently licensed organic producer that sells 100 percent
end products,” according to Gorenstein.
The $17 Million Bought Deal
Last week, Cronos announced
a bought deal public offering of approximately $17.3 million.
A bought deal “is in fact a true underwriting where an investment bank actually takes the entire transaction for itself and then
goes out and re-sells it to its clients,” Viridian Capital
Advisors’ Scott Greiper explained. “That’s not typical in any industry, and it shows the bullishness of Canadian investors in
cannabis,” he noted in relation to another
bought deal announced in December, where Supreme Pharmaceuticals Inc (CNSX: SL) (OTC: SPRWF) raised almost $41 million.
“In terms of institutional investors, I think one of the things that is unique about the way our company started is that our
actual initial funding was coming from institutional investors primarily in New York,” Gorenstein noted.
On this occasion, however, “We wanted to make sure that we were being inclusive and acting like a public company, creating
liquidity,” Gorenstein explained. “So, rather than doing another purely internal round of financing [like we had done last time],
we started having conversations with banks.”
Spending Millions Of Dollars
Javier Hasse: So, why did you seek this deal? What do you plan to use the proceeds for?
Gorenstein: There was a heavy amount of demand for a bought deal and for investment. We had essentially been
receiving indications of interest probably since October or November of 2016.
We just thought that the time was right to open an investor base and start to create liquidity and tell the story of what we’re
doing.
Part of why we really wanted to do this investment is [...] a license in Canada isn’t limited to plants, it isn’t based on
patients, it isn’t based on kilograms produced; it’s for an address. The opportunity we saw was really one of the largest land
packages that is available in the program.
We could build over 5 million square feet of production space on our land and not have to apply for any additional licenses. So,
we wanted the capital really just to start developing more of the land, building additional infrastructure and capacity because the
demand we’re seeing is extremely significant.
Hasse: Who would you sell all the extra cannabis to?
Gorenstein: I think if we were producing 10 times more product than we’re producing now, we would be able to
sell it really without any issues. Between Canada, Germany and other jurisdictions that we’ve been speaking to, there is a heavy
amount of demand.
Globally there is estimated to be a $200 billion revenue industry that already exists, and the consumer purchasing habits are
already there. We’re one of the first international suppliers to come online, so we want to build very quickly and very
aggressively to meet that demand.
Hasse: Are you planning to buy land adjacent to your licensed area to expand?
Gorenstein: We have 125 licensed acres, so we have plenty of space. I don’t believe anyone has more land than
that, that is zoned and licensed for cannabis production in Canada. We don’t really need to make any other land acquisitions.
Once we have 5 million square feet built, if at that point we think we still need to produce more, we could either do two
stories of production or we could look at land acquisition. But right now we’re focused on building out our footprint in Canada. I
think it’s unlikely we would make any very significant land acquisitions in Canada just because we are putting a lot of attention
on being a global supplier and distributor.
We think it’s very likely that by the end of the year we will have or will start to break ground on an international producer,
outside of Canada.
Hasse: Why would you be interested in producing outside of Canada?
Gorenstein: There are various reasons for that. I think that in terms of establishing (and really cementing)
your presence in another country it’s good to have a base of operations there; it’s good to create jobs and awareness of your brand
in the community. But also, there are some countries, that because of the nature of where they’re located in the world, the
humidity and sunlight profile, the climate, the water, the labor costs [...] you actually can produce cheaper in those locations
than you would be able to anywhere in Canada.
Hasse: Are you planning on making investments in verticals, like clinics or agtech companies, as
well?
Gorenstein: We haven’t invested in clinics because we’ve just seen there is a shortage in Canada. We’ve focused
our investments and our efforts on having the highest product quality, so that we would have organic patients come through. Even if
we were to lose every single patient we had in Canada, we’re pretty confident that we could ship all of our product internationally
and have nothing leftover.
As far as technology, agriculturally, we absolutely are investing in that, but we’re not investing in external companies; we’re
really investing in that in house.
Klein: You don’t see a lot of the larger pharmaceutical companies, the Pfizer Inc. (NYSE:
PFE)’s of the world, owning their method of distribution and
owning retail locations. So, as we expand our footprint and our distribution channels, we think we can do that focusing on our
operations and productions, without necessarily owning the retail centers and locations at this point in time.
Related Links:
Garbage Companies & The
Marijuana Industry: Expert Warns About Overvalued Cannabis Stocks
Why Education Could Be The Biggest Beneficiary Of
Cannabis Legalization
Getting Into The Business Of Medical
Marijuana: An Interview With IGC CEO Ram Mukunda
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.